BioRestorative Therapies (BRTX) Return on Capital Employed (2011 - 2025)
BioRestorative Therapies' (BRTX) quarterly Return on Capital Employed came in at 1374.66% in Q4 2025, down 125526.0% YoY from N/an in Q4 2024, and down 245.17% on a QoQ basis from 398.25% in Q3 2025.
BioRestorative Therapies (BRTX) Return on Capital Employed (2011 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 15 years of Return on Capital Employed data on file, last reported at 1374.66% in Q4 2025.
- Quarterly Return on Capital Employed fell 125526.0% year-over-year to 1374.66% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1374.66% (down 125526.0% YoY) and the FY2025 annual result came in at 351.08%, down 21822.0% from the prior year.
- Return on Capital Employed retreated to 1374.66% in Q4 2025, from 398.25% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 110.14% in Q2 2024 to a low of 1397.74% in Q3 2021.
- A 5-year average of 386.67% and a median of 196.11% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2021 — Return on Capital Employed soared 136325 bps — and 2025, when it sank 125526 bps.
- Tracing BRTX's Return on Capital Employed over 5 years: stood at 220.14% in 2021, then climbed by 23 bps to 169.48% in 2022, then rose by 15 bps to 143.6% in 2023, then advanced by 17 bps to 119.39% in 2024, then sank by 1051 bps to 1374.66% in 2025.
- The last three Return on Capital Employed figures came in at 1374.66% (Q4 2025), 398.25% (Q3 2025), and 227.63% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 7.88% |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.01 Mn | 17,964.00 | -1,374.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,374.66% |
| Sep 30, 2025 | -398.25% |
| Jun 30, 2025 | -227.63% |
| Mar 31, 2025 | -172.07% |
| Dec 31, 2024 | -119.39% |
| Sep 30, 2024 | -112.27% |
| Jun 30, 2024 | -110.14% |
| Mar 31, 2024 | -114.51% |
| Dec 31, 2023 | -143.60% |
| Sep 30, 2023 | -158.08% |
| Jun 30, 2023 | -583.14% |
| Mar 31, 2023 | -253.94% |
| Dec 31, 2022 | -169.48% |
| Sep 30, 2022 | -170.36% |
| Jun 30, 2022 | -132.39% |
| Mar 31, 2022 | -233.39% |
| Dec 31, 2021 | -220.14% |
| Sep 30, 2021 | -1,397.74% |
| Jun 30, 2021 | -1,020.77% |
| Mar 31, 2021 | -621.46% |